Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

368 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma.
Goyal L, Saha SK, Liu LY, Siravegna G, Leshchiner I, Ahronian LG, Lennerz JK, Vu P, Deshpande V, Kambadakone A, Mussolin B, Reyes S, Henderson L, Sun JE, Van Seventer EE, Gurski JM Jr, Baltschukat S, Schacher-Engstler B, Barys L, Stamm C, Furet P, Ryan DP, Stone JR, Iafrate AJ, Getz G, Porta DG, Tiedt R, Bardelli A, Juric D, Corcoran RB, Bardeesy N, Zhu AX. Goyal L, et al. Among authors: bardelli a. Cancer Discov. 2017 Mar;7(3):252-263. doi: 10.1158/2159-8290.CD-16-1000. Epub 2016 Dec 29. Cancer Discov. 2017. PMID: 28034880 Free PMC article.
A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.
Bertotti A, Migliardi G, Galimi F, Sassi F, Torti D, Isella C, Corà D, Di Nicolantonio F, Buscarino M, Petti C, Ribero D, Russolillo N, Muratore A, Massucco P, Pisacane A, Molinaro L, Valtorta E, Sartore-Bianchi A, Risio M, Capussotti L, Gambacorta M, Siena S, Medico E, Sapino A, Marsoni S, Comoglio PM, Bardelli A, Trusolino L. Bertotti A, et al. Among authors: bardelli a. Cancer Discov. 2011 Nov;1(6):508-23. doi: 10.1158/2159-8290.CD-11-0109. Epub 2011 Sep 2. Cancer Discov. 2011. PMID: 22586653 Free article.
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer.
Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, Valtorta E, Schiavo R, Buscarino M, Siravegna G, Bencardino K, Cercek A, Chen CT, Veronese S, Zanon C, Sartore-Bianchi A, Gambacorta M, Gallicchio M, Vakiani E, Boscaro V, Medico E, Weiser M, Siena S, Di Nicolantonio F, Solit D, Bardelli A. Misale S, et al. Among authors: bardelli a. Nature. 2012 Jun 28;486(7404):532-6. doi: 10.1038/nature11156. Nature. 2012. PMID: 22722830 Free PMC article.
Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer.
Bardelli A, Corso S, Bertotti A, Hobor S, Valtorta E, Siravegna G, Sartore-Bianchi A, Scala E, Cassingena A, Zecchin D, Apicella M, Migliardi G, Galimi F, Lauricella C, Zanon C, Perera T, Veronese S, Corti G, Amatu A, Gambacorta M, Diaz LA Jr, Sausen M, Velculescu VE, Comoglio P, Trusolino L, Di Nicolantonio F, Giordano S, Siena S. Bardelli A, et al. Cancer Discov. 2013 Jun;3(6):658-73. doi: 10.1158/2159-8290.CD-12-0558. Epub 2013 Jun 2. Cancer Discov. 2013. PMID: 23729478 Free PMC article.
Climbing RAS, the everest of oncogenes.
Russo M, Di Nicolantonio F, Bardelli A. Russo M, et al. Among authors: bardelli a. Cancer Discov. 2014 Jan;4(1):19-21. doi: 10.1158/2159-8290.CD-13-0906. Cancer Discov. 2014. PMID: 24402942
Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer.
Misale S, Arena S, Lamba S, Siravegna G, Lallo A, Hobor S, Russo M, Buscarino M, Lazzari L, Sartore-Bianchi A, Bencardino K, Amatu A, Lauricella C, Valtorta E, Siena S, Di Nicolantonio F, Bardelli A. Misale S, et al. Among authors: bardelli a. Sci Transl Med. 2014 Feb 19;6(224):224ra26. doi: 10.1126/scitranslmed.3007947. Sci Transl Med. 2014. PMID: 24553387 Free article.
Minimal residual disease in breast cancer: in blood veritas.
Siravegna G, Bardelli A. Siravegna G, et al. Among authors: bardelli a. Clin Cancer Res. 2014 May 15;20(10):2505-7. doi: 10.1158/1078-0432.CCR-14-0370. Epub 2014 Mar 21. Clin Cancer Res. 2014. PMID: 24658155 Free article.
Acquired resistance to EGFR-targeted therapies in colorectal cancer.
Van Emburgh BO, Sartore-Bianchi A, Di Nicolantonio F, Siena S, Bardelli A. Van Emburgh BO, et al. Among authors: bardelli a. Mol Oncol. 2014 Sep 12;8(6):1084-94. doi: 10.1016/j.molonc.2014.05.003. Epub 2014 May 14. Mol Oncol. 2014. PMID: 24913799 Free PMC article. Review.
368 results